Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Short Interest Up 254.8% in March

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) was the recipient of a significant increase in short interest in March. As of March 15th, there was short interest totalling 51,800 shares, an increase of 254.8% from the February 28th total of 14,600 shares. Based on an average daily volume of 85,100 shares, the short-interest ratio is presently 0.6 days. Currently, 0.0% of the shares of the stock are sold short.

Fresenius SE & Co. KGaA Price Performance

OTCMKTS:FSNUY opened at $10.92 on Friday. Fresenius SE & Co. KGaA has a 52-week low of $6.57 and a 52-week high of $11.23. The company has a quick ratio of 1.05, a current ratio of 1.36 and a debt-to-equity ratio of 0.57. The firm has a market cap of $24.40 billion, a P/E ratio of 52.00 and a beta of 1.02. The business’s 50-day moving average price is $10.16 and its 200 day moving average price is $9.45.

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) last released its earnings results on Wednesday, February 26th. The company reported $0.18 EPS for the quarter. The business had revenue of $6.01 billion during the quarter. As a group, sell-side analysts predict that Fresenius SE & Co. KGaA will post 0.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Fresenius SE & Co. KGaA in a research note on Monday, February 3rd.

Fresenius SE & Co. KGaA Company Profile

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.